Trial Profile

A Prospective, Randomized, Open Study on the Efficacy and Safety of the GnRH Analogue Triptorelin for HIV-1 Reservoir Reduction in ART Treated HIV-1 Infected Patients

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 05 Jan 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Triptorelin (Primary) ; Integrase inhibitors; Non-nucleoside reverse transcriptase inhibitors; Nucleoside reverse transcriptase inhibitors; Peptide hydrolase inhibitors
Indications HIV-1 infections
Focus Therapeutic Use
Sponsors Immune System Regulation

11 Nov 2020 Planned End Date changed from 1 Dec 2020 to 1 Dec 2021.
11 Nov 2020 Planned primary completion date changed from 1 Sep 2020 to 1 Aug 2021.
13 Oct 2020 According to an Immune System Regulation media release, the infection clinics have been fully occupied with caring for Corona patients during the ongoing pandemic and the Medical Products Agency has advised against inclusion in clinical trials and the company can now speed up patient recruitment to the study.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com